Navigation Links
Bisexuality not a transitional phase among women, according to new research
Date:1/15/2008

WASHINGTON -- Bisexuality in women appears to be a distinctive sexual orientation and not an experimental or transitional stage that some women adopt "on their way" to lesbianism, according to new research published by the American Psychological Association.

The study of 79 non-heterosexual women over 10 years found that bisexual women maintained a stable pattern of attraction to both sexes. In addition, the research appears to have debunked the stereotype that bisexual women are uninterested in or unable to commit to long-term monogamous relationships.

"This research provides the first empirical examination of competing assumptions about the nature of bisexuality, both as a sexual identity label and as a pattern of nonexclusive sexual attraction and behavior," wrote University of Utah psychologist Lisa M. Diamond, PhD, who conducted the study. "The findings demonstrate considerable fluidity in bisexual, unlabeled and lesbian women's attractions, behaviors and identities and contribute to researchers' understanding of the complexity of sexual-minority development over the life span."

Results of the research were published in the January issue of Developmental Psychology, published by the APA. This special issue of the journal focuses on research into psychological topics concerning sexual orientation and gender identity.

Diamond used interview data collected five times over a decade from 79 women who identified as lesbian, bisexual or unlabeled. The subjects initially ranged in age from 18 to 25 years old.

Among Diamond's findings:

  • Bisexual and unlabeled women were more likely than lesbians to change their identity over the course of the study, but they tended to switch between bisexual and unlabeled rather than to settle on lesbian or heterosexual as their identities.

  • Seventeen percent of respondents switched from a bisexual or unlabeled identity to heterosexual during the study -- but more than half of these women switched back to bisexual or unlabeled by the end.

  • By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.

  • Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.

"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.


'/>"/>

Contact: Pam Willenz
pwillenz@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Seabrook House Opens Transitional Living Facility: Seabrook West
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. Cytopia Commences Phase II Cancer Drug Study
6. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
7. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
8. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
9. Early Phase II results show bosutinib safe, effective for CML
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, ... group. But his impoverished upbringing and life experiences could have led him down a ... Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal ...
(Date:2/27/2017)... Orange County, CA (PRWEB) , ... February 27, 2017 , ... ... for periodontitis. Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria ... of deep cleaning, also referred to as a scaling and root planing or SRP, ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design ... Edition of International Social Design Awards. , The 7th A' Social Design ... Governments and Institutions worldwide with realized projects and conceptual works. , The first ...
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) ... its 2017 outlook and related key planning assumptions. Executive Summary ... a 2 percent increase compared to the prior year. ... $10 million compared to net income of $15 million in ... was $24 million compared to adjusted net income of $27 ...
(Date:2/27/2017)... 27, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), ... molecular diagnostic tests and pathology services, announced today the ... upcoming United States and Canadian ... 2017 in San Antonio, Texas . ... data from the Company,s extensive experience in molecular thyroid ...
Breaking Medicine Technology: